Revium Rx. (RVRC): Total Assets
$8.30M
As of 2025-12-31
$7.11M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.30M | -59.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $20.28M | n/a | 2026-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Revium Rx. (RVRC) | 2025-12-31 | $8.30M | -59.1% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $8.23M | -95.0% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $8.36M | +21.2% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $8.11M | n/a |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $8.62M | -0.9% |
| GRI Bio, Inc. (GRI) | 2025-12-31 | $8.67M | +51.0% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $7.86M | +122.5% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $7.81M | +142.0% |
Compare RVRC, LNAI, XBIO, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗